The high expression frequency of both IDO1 and PD-L1 in EC suggests that therapies targeting only the PD-1/PD-L1 axis may be turned down in this tumor type due to IDO1 interference with immune cell function (Figure 2). The gene discussed is PDCD1; the disease is neoplasm.